Summary & Overview
HCPCS Level II J3570: Laetrile (amygdalin, vitamin B17)
HCPCS Level II code J3570 codes for Laetrile (amygdalin, vitamin B17), an agent historically promoted as an alternative therapeutic compound. While not a common, evidence-based therapy in mainstream clinical practice, the code exists to identify the supply or administration of this specific agent in billing systems. Nationally, its presence in HCPCS reflects the need for discrete reporting when such products are provided, whether in outpatient infusion suites, clinics, or other ambulatory settings.
This analysis covers key payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find an overview of coding intent, payer coverage considerations, and the clinical context in which J3570 may appear. The publication outlines typical service lines and sites of care associated with HCPCS billing for therapeutic agents, summarizes what documentation and coding practice elements are relevant, and highlights where input data is not available.
The piece is intended to inform billing staff, clinical coders, and policy analysts about the classification and reporting of J3570, benchmarks where available, and the broader implications for claims processing and payer adjudication. Data not available in the input.
Billing Code Overview
HCPCS Level II code J3570 represents Laetrile (amygdalin, vitamin B17) as described in the code definition. The service is the administration or supply of a biologic/therapeutic agent described as Laetrile (amygdalin, vitamin B17). The typical site of service for this code is outpatient infusion or clinic administration settings where injectable or infused therapeutic agents are provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient seeks or is receiving an injectable or oral preparation labeled as J3570 (Laetrile, amygdalin, vitamin b17) most commonly in an outpatient infusion clinic, oncology integrative medicine clinic, or complementary/alternative medicine practice. A typical scenario involves an adult with a history of cancer or a patient pursuing alternative anticancer therapy who presents for administration or supply of the agent. The clinical workflow includes: pre-visit medication reconciliation and informed consent discussing experimental/alternative status; verification of prescription or provider order; screening for contraindications (e.g., pregnancy, known cyanide metabolism disorders); preparation and compounding by pharmacy if needed; administration by a licensed nurse or dispensing for patient self-administration with counseling on dosing and signs of toxicity; and documentation of lot numbers, dose, route, and any adverse events. Billing staff select J3570 for the drug supply; appropriate modifiers are appended when applicable (e.g., for unusual procedural circumstances, reduced services, or provider-based billing). Patient monitoring includes vital signs during and after administration and follow-up to document treatment tolerance and any laboratory monitoring for toxicity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |